google :Dept of Defense, NYTimes, and MD Anderson Ctr , rated #2 in world by Consumer Rports., google each of these and Neuvax by GALE...
Sentiment: Strong Buy
Galena Biopharma, Inc. ("Galena" or the "Company") (GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major medical needs across the full spectrum of cancer care announced today the execution of a purchase agreement for up to $55.0 million with Lincoln Park Capital Fund, LLC ("LPC"), a Chicago-based institutional investor.
Under the terms of the purchase agreement dated November 18, 2014, LPC initially purchased $5.0 million dollars of Galena common stock at a price of $2.00 per share, 9% higher than the market close as of November 18, 2014. Thereafter, at its sole discretion, Galena may sell up to $50 million worth of common stock to LPC over the 36-month term of the purchase agreement, subject to the conditions and limitations set forth in the purchase agreement. Under the terms of the purchase agreement, LPC will not cause or engage in any manner whatsoever, any direct or indirect short selling or hedging of Galena common stock and is obligated to purchase at times and amounts controlled by the Company. In consideration for entering into the agreement the Company issued shares of its common stock to LPC as a commitment fee.
Galena plans to use the proceeds received for its commercial and product development activities and for other working capital and general corporate purposes.
Mark W. Schwartz, Ph.D., President and Chief Executive Officer of Galena Biopharma, stated, "This funding mechanism from Lincoln Park Capital, an established healthcare investment firm, provides Galena with strategic, long-term access to capital in order to execute on our clinical and commercial programs as we approach multiple milestones over the next several quarters. Importantly, this structure allows us complete control and flexibility to access capital at the appropriate times, coinciding with the progress of the Company."
Sentiment: Strong Buy
This is some of the best English I ever seen you use......stupid lil man......
G#$%$le Enrollment completed six months #$%$he#$%$d of schedule
Ph#$%$se 1 #$%$nd e#$%$rly Ph#$%$se 2 d#$%$t#$%$ to be presented #$%$t the Americ#$%$n Society of Hem#$%$tology 56th Annu#$%$l Meeting in December, with top-line d#$%$t#$%$ in mid-ye#$%$r 2015
PORTLAND, Ore., Nov. 18, 2014 (GLOBE NEWSWIRE) -- G#$%$len#$%$ Bioph#$%$rm#$%$, Inc. (GALE), #$%$ bioph#$%$rm#$%$ceutic#$%$l comp#$%$ny developing #$%$nd commerci#$%$lizing innov#$%$tive, t#$%$rgeted oncology tre#$%$tments th#$%$t #$%$ddress m#$%$jor medic#$%$l needs #$%$cross the full spectrum of c#$%$ncer c#$%$re, tod#$%$y #$%$nnounced the completion of enrollment in the GALE-401, or An#$%$grelide Controlled Rele#$%$se, Ph#$%$se 2 Clinic#$%$l Tri#$%$l. The Ph#$%$se 2, clinic#$%$l proof-of-concept study is tre#$%$ting 18 p#$%$tients with elev#$%$ted pl#$%$telet counts in myeloprolifer#$%$tive neopl#$%$sms (MPNs) including Essenti#$%$l Thrombocythemi#$%$ (ET), Polycythemi#$%$ Ver#$%$ (PV), #$%$nd Prim#$%$ry Myelofibrosis (PMF).
Sentiment: Strong Buy
Where are you getting your information? As far as I can tell, tivantinib is not being studied for Her2 positive breast cancer. If you are going to pump the stock, at least do it correctly.
If you could figure this out , what makes you think any Co would buy it with this bad data ?????????
Do you really believe anything you wrote here, "mdan599", or are you just trying to be funny and provocative? You have to know your accusations are outlandish and far-fetched. To think all of those parties (with all of that money at-risk) would conspire as you suggest--you have to be kidding. I do like your optimism that Puma will be back to $250 in a few weeks though, but believe that is dependent on the NSABP FB-7 readout. If it is good, as many hope and expect (and the G3 diarrhea is single digits with Imodium prophylaxis), you may in fact be correct, if not light in your estimation.
WOW, you are incredibly naïve. Do you really think a company can be scammed into spending 7 billion?
Think about the entire situation before shorting. The CEO comes out with a bold faced lie calling data from a failed trial positive and the stk drops only 10%. Shocking in a general context but not for this co with 85% institutional shareholders and 14% insider shareholders who all huddle together to keep the stk up with the goal of scamming some wayward co that does a poor job at vetting puma and buys the co for billions of dollars and ends up with a failed drug.
He gets away with all this because he has the backing of the institutions that hold most of the stk and will not sell the stk unless it looks hopeless for a buyout and the sell-side analysts that incessantly pump the stk to create a perception that the puma drug will bring in billion of dollars and is better than Herceptin when in reality the drug is mediocre at best and the treatment landscape has shifted away from Herceptin as SOC and now includes drugs like Perjeta and Kadcyla. All this is being done to scam a co to acquire puma at outsized valuations. The sell-side analysts are pumping the stk because higher the sale value of puma higher the commissions for bank(s) that manage the sale. The institutions are doing it because they are positioned to reap millions if not billions of dollars if the co is sold now, selling shares could reduce their returns. Obviously, insiders are not selling because they will make millions of dollars with little or no investments if the co gets sold soon as they are expecting it will.
With almost all the stk of puma held by insiders and institutional investors they manage the stk price by trading between themselves and keeping the stk price between 200 and 250 no matter what news comes out. Therefore no matter if the Extenet complete results reporting is delayed by 2 1/2 years since primary endpoint and 1 1/2 year since completion of study, no matter the CEO tells a bold face lie calling failed results positive, the stock loses only 10%, it'll be back at 250 in weeks.
Dude, use your common sense and your brain. Sponsor can start a phase 3 pivotal trial based on what they see from phase 2 at their own expense and risk. FDA will ok if the safety signal is reasonable.
Puma has a decent shot at another successful phase 3 trial in another setting which will add more value to the company.
If neratinib were expected to be better than herceptin, the ORR would have to be close to 100 percent as herceptin was 76 percent. This will not happen on earth. Otherwise puma would have been valued at 50 billion instead of 7 billion.
Your whining without understanding the oncology business makes u look like an ignorant idiot.
All of this information is already priced into the current valuation. So good news holds current price. Bad news sends it lower.